Study on the stability of PBMCs recovered from leukocyte-depleted filter residues
10.13303/j.cjbt.issn.1004-549x.2025.05.020
- VernacularTitle:从滤白残留物中回收单个核细胞的稳定性研究
- Author:
Ju LIN
1
;
Zhiqiang XIANG
2
;
Dongfen DU
1
;
Fang YUAN
1
;
Miaoyu WANG
1
;
Yue WU
2
;
Kaiyu HUANG
1
;
Lieyong SANG
1
Author Information
1. Shaoxing Blood Center, Shaoxing 312071, China
2. RuiChuang Biotechnology Co., Ltd.Shaoxing 312065, China
- Publication Type:Journal Article
- Keywords:
leukocyte filter;
backflush solution;
leukocyte-depleted filter residues;
peripheral blood mononuclear cells (PBMCs)
- From:
Chinese Journal of Blood Transfusion
2025;38(5):723-733
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To identify an optimal back-flush solution for leukocyte-depleted filters that maximizes peripheral blood mononuclear cell (PBMC) recovery with high viability, long-term storage stability, and sterility of the harvested residues, thereby providing a clinically translatable strategy. Methods: Three sterile bag-packaged solutions—Saline, Solvent, and Hanks' balanced salt solution (HBSS)—were used to back-flush randomly assigned leukocyte-depleted filters. Nucleated cell recovery rate and viability of the harvested residues were compared. The optimal solution identified was applied to an expanded sample set. PBMC viability and yield were evaluated after 1h vs 48h storage of the residues. PBMCs isolated from the residues were cryopreserved in liquid nitrogen for 1 month, followed by post-thaw comparisons of viability and T-cell expansion capacity. Results: The Solvent group achieved the highest and most consistent nucleated cell recovery rate. Post-flush recovery rate from filters after 400 mL whole blood processing was (21.3±1.6)% for the Solvent group, significantly higher than Saline group (19.2±6.3)% and HBSS group (11.2±5.0)%, with residues from all groups maintaining viability >90%. No biologically significant difference in residue viability was observed between 48h vs 1h storage groups (93.3±2.3)% vs (95.7±1.8)%). PBMC recovery rates from residues showed no statistical difference between 48h vs 1h storage groups [(48.2%±9.5%)vs (40.41%±8.35%), P>0.05], with (17.7±2.6)×10
cells. After 1-month cryopreservation and 10-day expansion, PBMCs isolated from 48-hour-stored residues retained (91.2±3.2)% viability and achieved a (61.9±15.9)-fold expansion. Conclusion: The bag-packaged Solvent, as a back-flush solution, enables sterile acquisition of leukocyte-depleted filter residues through closed-system tubing connections. These residues maintained PBMC viability and recovery rates after 48h storage at 2℃-8℃, with post-cryopreservation (1-month liquid nitrogen) viability and expansion capacity remaining stable. This protocol complies with blood bank regulatory criteria, addresses the concerns about the infectious window period in cell therapy raw materials, and provides a clinically translatable strategy for PBMC-based applications.
